Tag Archive for: CEO appointment

Genopore appoints Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company

/in

San Francisco, California – Yavne, Israel – July 14th, 2026 – Genopore, the next-generation proteomics company developing the first semiconductor based optical nanopore technology platform with AI/ML analysis for direct single protein molecule identification and digital quantification, today announced the appointment of life science leader Rey Mali as its new Chief Executive Officer, with immediate […]

Read more

Christian Wichert appointed Chief Executive Officer to lead next phase of growth

/in

Senior executive across industrial biotechnology and consumer markets with strong expertise in commercialization joins AMSilk as the Company advances from development through scale-up to market growth The announcement follows the launch of biotech silk protein yarns in Balenciaga Spring 2026 collection Neuried, Germany, June 17, 2026 – AMSilk GmbH (“AMSilk”), a global leader in advanced […]

Read more

Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic

/in

Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher Bio Follows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine release Commit is poised to nominate its first two clinical development candidates later in 2026 COPENHAGEN, Denmark — March 11, 2026 — Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed […]

Read more

Hans Schambye Appointed as Chief Executive Officer of BOOST Pharma

/in

Advancing development of lead candidate BT-101, a potential disease-modifying treatment for Brittle Bone Disease Preparing for Phase III development following promising data showing reduced fractures in affected children Stockholm, Sweden, February 10, 2026 – BOOST Pharma (“BOOST” or the “Company), a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal […]

Read more

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines

/in

– 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding – Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials COVENTRY, England, Jan. 8, 2026 /PRNewswire/ — NanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics, […]

Read more
© Optimum Strategic Communications.